Risks of Digestive System Side-Effects of Selective Serotonin Reuptake Inhibitors in Patients with Depression: A Network Meta-Analysis

References

• Vadodaria KC, Ji Y, Skime M., et al. Serotonin-induced hyperactivity in SSRI-resistant major depressive disorder patient-derived neurons. Mol Psychiatry. 2019;24(6):795–807. doi:10.1038/s41380-019-0363-y
   PubMed Web of Science ®Google Scholar
• Fischer Fumeaux CJ, Morisod Harari M, Weisskopf E, et al. Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence - an update. Expert Opin Drug Saf. 2019;18(10):949–963. doi:10.1080/14740338.2019.1658740
   PubMed Web of Science ®Google Scholar
• Furukawa TA, Cipriani A, Cowen PJ, Leucht S, Egger M, Salanti G. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry. 2019;6(7):601–609. doi:10.1016/S2215-0366(19)30217-2
   PubMed Web of Science ®Google Scholar
• Plenge P, Abramyan AM, Sørensen G, et al. The mechanism of a high-affinity allosteric inhibitor of the serotonin transporter. Nat Commun. 2020;11(1):1491. doi:10.1038/s41467-020-15292-y
   PubMed Web of Science ®Google Scholar
• Yaman B, Bal R. Pindolol potentiates the antidepressant effect of venlafaxine by inhibiting 5-HT1A receptor in DRN neurons of mice. Int J Neurosci. 2022;132(1):23–30. doi:10.1080/00207454.2020.1797723
   PubMed Web of Science ®Google Scholar
• Cussotto S, Strain CR, Fouhy F, et al. Differential effects of psychotropic drugs on microbiome composition and gastrointestinal function. Psychopharmacology. 2019;236(5):1671–1685. doi:10.1007/s00213-018-5006-5
   PubMed Web of Science ®Google Scholar
• Golden RN. Making advances where it matters: improving outcomes in mood and anxiety disorders. CNS Spectr. 2004;9(6 Suppl 4):14–22. doi:10.1017/S1092852900025463
   PubMed Web of Science ®Google Scholar
• Kostev K, Rex J, Eith T, Heilmaier C. Which adverse effects influence the dropout rate in selective serotonin reuptake inhibitor (SSRI) treatment? Results for 50,824 patients. German Med Sci. 2014;12:Doc15. doi:10.3205/000200
   PubMedGoogle Scholar
• Zou C, Ding X, Flaherty JH, Dong B. Clinical efficacy and safety of fluoxetine in generalized anxiety disorder in Chinese patients. Neuropsychiatr Dis Treat. 2013;9:1661–1670. doi:10.2147/NDT.S38899
   PubMed Web of Science ®Google Scholar
• Mead E, Atkinson G, Richter B, et al. Drug interventions for the treatment of obesity in children and adolescents. Cochrane Database Syst Rev. 2016;11(11):Cd012436. doi:10.1002/14651858.CD012436
   PubMed Web of Science ®Google Scholar
• Talley NJ. How effective is fluoxetine for the treatment of pain and constipation-predominant irritable bowel syndrome? Nat Clin Pract Gastroenterol Hepatol. 2006;3(4):196–197. doi:10.1038/ncpgasthep0444
   PubMedGoogle Scholar
• Yrondi A, Fiori LM, Frey BN, et al. Association between side effects and blood microrna expression levels and their targeted pathways in patients with major depressive disorder treated by a selective serotonin reuptake inhibitor, escitalopram: a CAN-BIND-1 report. int j neuropsychopharmacol. 2020;23(2):88–95. doi:10.1093/ijnp/pyz066
   PubMed Web of Science ®Google Scholar
• Janssen P, Van Oudenhove L, Casteels C, Vos R, Verbeke K, Tack J. The effects of acute citalopram dosing on gastric motor function and nutrient tolerance in healthy volunteers. Aliment Pharmacol Ther. 2011;33(3):395–402. doi:10.1111/j.1365-2036.2010.04522.x
   PubMed Web of Science ®Google Scholar
• Kocabay G, Yildiz M, Eksi Duran N, Ozkan M. Sinus arrest due to sertraline. Clin Cardiol. 2010;33(6):E114–115. doi:10.1002/clc.20647
   PubMedGoogle Scholar
• Afzal A, Ajmal K, Shakir S, Khan BT, Ara I. Paroxetine: an update of response on intestinal motility. J Pak Med Assoc. 2016;66(3):240–242.
   PubMed Web of Science ®Google Scholar
• Coates MD, Johnson AC, Greenwood-Van Meerveld B, Mawe GM. Effects of serotonin transporter inhibition on gastrointestinal motility and colonic sensitivity in the mouse. Neurogastroenterol Motility. 2006;18(6):464–471. doi:10.1111/j.1365-2982.2006.00792.x
   PubMed Web of Science ®Google Scholar
• Cohn CK, Shrivastava R, Mendels J, et al. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry. 1990;51:28–33.
   PubMed Web of Science ®Google Scholar
• Mathews M, Gommoll C, Chen D, Nunez R, Khan A. Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 2015;30(2):67–74. doi:10.1097/YIC.0000000000000057
   PubMed Web of Science ®Google Scholar
• Gartlehner G, Hansen RA, Morgan LC, et al. AHRQ Comparative Effectiveness Reviews. Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011.
   Google Scholar
• Kadam RL, Sontakke SD, Tiple P, Motghare VM, Bajait CS, Kalikar MV. Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: a randomized, parallel, open-label clinical study. Indian J Pharmacol. 2020;52(2):79–85. doi:10.4103/ijp.IJP_441_18
   PubMed Web of Science ®Google Scholar
• Oliva V, Lippi M, Paci R, et al. Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: a systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2021;109:110266. doi:10.1016/j.pnpbp.2021.110266
   PubMed Web of Science ®Google Scholar
• Solmi M, Fornaro M, Ostinelli EG, et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry. 2020;19(2):214–232. doi:10.1002/wps.20765
   PubMed Web of Science ®Google Scholar
• Guo S, Yang Y, Pei XJ, Liu FY. Comparative risk of Selective Serotonin Reuptake Inhibitors (SSRIs)-induced nausea among Chinese senile depression patients: a network meta-analysis of randomized-controlled trials. Medicine. 2020;99(7):e19133. doi:10.1097/MD.0000000000019133
   PubMed Web of Science ®Google Scholar
• Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Clin Ther. 2007;29(11):2319–2332. doi:10.1016/j.clinthera.2007.11.014
   PubMed Web of Science ®Google Scholar
• Wade A, Michael Lemming O, Bang Hedegaard K. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol. 2002;17(3):95–102. doi:10.1097/00004850-200205000-00001
   PubMed Web of Science ®Google Scholar
• Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol. 2005;20(3):131–137. doi:10.1097/00004850-200505000-00002
   PubMed Web of Science ®Google Scholar
• Valle-Cabrera R, Mendoza-Rodríguez Y, Robaina-García M, et al. Efficacy of sertraline in patients with major depressive disorder naive to selective serotonin reuptake inhibitors: a 10-week randomized, Multicenter, Placebo-Controlled, Double-Blind, Academic Clinical Trial. J Clin Psychopharmacol. 2018;38(5):454–459. doi:10.1097/JCP.0000000000000950
   PubMed Web of Science ®Google Scholar
• Mao PX, Tang YL, Jiang F, et al. Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. Depress Anxiety. 2008;25(1):46–54. doi:10.1002/da.20222
   PubMed Web of Science ®Google Scholar
• Dunbar GC, Claghorn JL, Kiev A, Rickels K, Smith WT. A comparison of paroxetine and placebo in depressed outpatients. Acta Psychiatr Scand. 1993;87(5):302–305. doi:10.1111/j.1600-0447.1993.tb03376.x
   PubMed Web of Science ®Google Scholar
• Hsu JW, Su TP, Huang CY, Chen YS, Chou YH. Faster onset of antidepressant effects of citalopram compared with sertraline in drug-naïve first-episode major depressive disorder in a Chinese population: a 6-week double-blind, randomized comparative study. J Clin Psychopharmacol. 2011;31(5):577–581. doi:10.1097/JCP.0b013e31822c091a
   PubMed Web of Science ®Google Scholar
• Ou JJ, Xun GL, Wu RR, et al. Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study. Psychopharmacology. 2011;213(2–3):639–646. doi:10.1007/s00213-010-1822-y
   PubMed Web of Science ®Google Scholar
• Woo YS, McIntyre RS, Kim JB, et al. Paroxetine versus venlafaxine and escitalopram in Korean patients with major depressive disorder: a randomized, rater-blinded, six-week study. Clin Psychopharmacol Neurosci. 2017;15(4):391–401. doi:10.9758/cpn.2017.15.4.391
   PubMed Web of Science ®Google Scholar
• Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur neuropsychopharmacol. 2004;14(6):457–470. doi:10.1016/j.euroneuro.2004.01.002
   PubMed Web of Science ®Google Scholar
• Perahia DG, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur psychiatr. 2006;21(6):367–378. doi:10.1016/j.eurpsy.2006.03.004
   PubMed Web of Science ®Google Scholar
• Croft H, Settle E Jr, Houser T, Batey SR, Donahue RM, Ascher JA. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther. 1999;21(4):643–658. doi:10.1016/S0149-2918(00)88317-4
   PubMed Web of Science ®Google Scholar
• Rickels K, Amsterdam J, Clary C, Fox I, Schweizer E, Weise C. A placebo-controlled, double-blind, clinical trial of paroxetine in depressed outpatients. Acta Psychiatr Scand Suppl. 1989;350:117–123. doi:10.1111/j.1600-0447.1989.tb07188.x
   PubMedGoogle Scholar
• Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol. 2004;24(4):389–399. doi:10.1097/01.jcp.0000132448.65972.d9
   PubMed Web of Science ®Google Scholar
• Lepola UM, Loft H, Reines EH. Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol. 2003;18(4):211–217. doi:10.1097/00004850-200307000-00003
   PubMed Web of Science ®Google Scholar
• Wang Y. Comparison of the effects of escitalopram and citalopram in the treatment of depression. Strait Pharma J. 2016;28(12):119–120.
   Google Scholar
• Zhou Z. Clinical efficacy and adverse reactions of escitalopram and paroxetine in the treatment of single depression. Contemp Med. 2018;24(22):152–153.
   Google Scholar
• Zhu Y. Analysis of the therapeutic effect of escitalopram oxalate and paroxetine hydrochloride on 46 patients with depression. Contemp Med. 2015;21(05):150–151.
   Google Scholar
• Liu R, Yu Z. Wu X. The efficacy and side effects of escitalopram in the treatment of depression. Jilin med j. 2013;34(24):4871–4872.
   Google Scholar
• Xu Y, Pan X, Pan X, Hao C, Deng Y. A controlled study of escitalopram and citalopram in the treatment of depression. J Clin psychiatry. 2011;21(01):42.
   Google Scholar
• Wang X, Han D, Wang L. Escitalopram vs. Fluoxetine in the Treatment of Depression: A Control Study. Eval Anal Drug-Use Hospital China. 2010;10(07):620–622.
   Google Scholar
• Zhang X, Xu X. Comparison of the treatment of Escitalopram and Sertraline for depression. Med j Chinese People’s Health. 2010;22(17):2205–2206+2209.
   Google Scholar
• Hu M, Li Y, Lu X, Xu G, Chen J. Escitalopram vs citalopram for depression: a randomized, double-blind, double-dummy, multicenter parallel controlled study. Central South Pharmacy. 2010;8(01):67–69.
   Google Scholar
• Xun G, Li Y, Zhao J, et al. Escitalopram vs citalopram in treatment of depression: a randomized, double-blind, double-dummy, multicenter parallel controlled study. Chin J New Drugs Clin Rem. 2009;28(04):263–267.
   Google Scholar
• Liu X, Zhang Y, Tan Q, Chen Y, Wang Z, Nie D. A controlled study in the treatment of depression with escitalopram and paroxetine. J Clin psychiatr. 2009;19(03):177–178.
   Google Scholar
• Yang R. A comparative study of citalopram and paroxetine in the treatment of depression. Shanxi Med j. 2008;37(06):563.
   Google Scholar
• Jin X, Xu X, Xu D, Yy C. Clinical efficacy and safety of escitalopram oxalate versus paroxetine in the treatment of unipolar depression. Chin J Clin Pharmacol. 2015;31(10):812–814.
   Google Scholar
• Nierenberg AA, Greist JH, Mallinckrodt CH, et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin. 2007;23(2):401–416. doi:10.1185/030079906X167453
   PubMed Web of Science ®Google Scholar
• Xu F, Xu L. Escitalopram vs. Fluoxetine for Depression: A Control Study. China Pharm. 2009;20(14):1084–1086.
   Google Scholar
• Cen L, Zou J, Tong J. Comparative study  on escitalopram and paroxetine in the treatment of depression. Shanghai arch psychiatr. 2009;21(01):41–42.
   Google Scholar
• Yu YQ, Zhang YL, Wang Z, et al. Involvement of proBDNF in Monocytes/Macrophages with gastrointestinal disorders in depressive mice. Neurotox Res. 2020;38(4):887–899. doi:10.1007/s12640-020-00235-8
   PubMed Web of Science ®Google Scholar
• Liu Y, Zou GJ, Tu BX, et al. Corticosterone induced the increase of proBDNF in primary hippocampal neurons via endoplasmic reticulum stress. Neurotox Res. 2020;38(2):370–384. doi:10.1007/s12640-020-00201-4
   PubMed Web of Science ®Google Scholar
• Lin LY, Kelliny S, Liu LC, Al-Hawwas M, Zhou XF, Bobrovskaya L. Peripheral ProBDNF delivered by an AAV vector to the muscle triggers depression-like behaviours in mice. Neurotox Res. 2020;38(3):626–639. doi:10.1007/s12640-020-00256-3
   PubMed Web of Science ®Google Scholar
• Walker JK, Gainetdinov RR, Mangel AW, Caron MG, Shetzline MA. Mice lacking the dopamine transporter display altered regulation of distal colonic motility. Am J Physiol Gastrointest Liver Physiol. 2000;279(2):G311–318. doi:10.1152/ajpgi.2000.279.2.G311
   PubMed Web of Science ®Google Scholar
• Matsushima Y, Terada K, Kamei C, Sugimoto Y. Sertraline inhibits nerve growth factor-induced neurite outgrowth in PC12 cells via a mechanism involving the sigma-1 receptor. Eur J Pharmacol. 2019;853:129–135. doi:10.1016/j.ejphar.2019.03.032
   PubMed Web of Science ®Google Scholar
• Baudry A, Pietri M, Launay JM, Kellermann O, Schneider B. Multifaceted regulations of the serotonin transporter: impact on antidepressant response. Front Neurosci. 2019;13:91. doi:10.3389/fnins.2019.00091
   PubMed Web of Science ®Google Scholar
• Frizzo ME. Can a selective serotonin reuptake inhibitor act as a glutamatergic modulator? Curr Ther Res Clin Exp. 2017;87:9–12. doi:10.1016/j.curtheres.2017.07.001
   PubMed Web of Science ®Google Scholar
• Lee HA, Kim KS, Hyun SA, Park SG, Kim SJ. Wide spectrum of inhibitory effects of sertraline on cardiac ion channels. Korean j Physiol Pharmacol. 2012;16(5):327–332. doi:10.4196/kjpp.2012.16.5.327
   PubMed Web of Science ®Google Scholar
• Singhal M, Manzella C, Soni V, et al. Role of SHP2 protein tyrosine phosphatase in SERT inhibition by enteropathogenic E. coli (EPEC). Am J Physiol Gastrointest Liver Physiol. 2017;312(5):G443–g449. doi:10.1152/ajpgi.00011.2017
   PubMed Web of Science ®Google Scholar
• Zhong W, Shahbaz O, Teskey G, et al. Mechanisms of nausea and vomiting: current knowledge and recent advances in intracellular emetic signaling systems. Int J Mol Sci. 2021;22(11):5797. doi:10.3390/ijms22115797
   PubMed Web of Science ®Google Scholar
• Dong C, Zhang JC, Yao W, et al. Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration. Pharmacol Biochem Behav. 2016;144:7–12. doi:10.1016/j.pbb.2016.02.005
   PubMed Web of Science ®Google Scholar
• Zurita-Turk M, Mendes Souza B, Prósperi de Castro C, et al. Attenuation of intestinal inflammation in IL-10 deficient mice by a plasmid carrying Lactococcus lactis strain. BMC Biotechnol. 2020;20(1):38. doi:10.1186/s12896-020-00631-0
   PubMed Web of Science ®Google Scholar
• David DJ, Bourin M, Jego G, Przybylski C, Jolliet P, Gardier AM. Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice. Br J Pharmacol. 2003;140(6):1128–1136. doi:10.1038/sj.bjp.0705538
   PubMed Web of Science ®Google Scholar
• Song J, Wang T, Zhang X, Li B, Zhu C, Zhang S. Upregulation of gastric norepinephrine with beta-adrenoceptors and gastric dysmotility in a rat model of functional dyspepsia. Physiol Res. 2020;69(1):135–143. doi:10.33549/physiolres.934169
   PubMed Web of Science ®Google Scholar